CERE News and Press, Ceres Inc. From 05/17/21

Cerevel Therapeutics Holdings, Inc. (CERE) Q1 2021 Results Earnings Conference Call May 17, 2021, 08:00 AM ET Company Participants Matt Calistri - Vice President, Investor Relations Tony Coles - Chairperson & Chief Executive Officer Abraham Ceesay - President Ray Sanchez - Chief Medical O...

Cerevel Therapeutics (CERE): Q1 GAAP EPS of -$0.40.Cash and cash equivalents as of March 31, 2021 were $343.4M.Press Release For further details see: Cerevel Therapeutics reports Q1 results

Announced strategic $125 million non-dilutive financing for tavapadon Welcomed Abraham Ceesay as President Appointed Scott Akamine as Chief Legal Officer Phase 1b trial for CVL-231 in schizophrenia on track for data mid-year 2021 Phase 1 acute anxiety dat...

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2021 financial results on Monday, May 17, ...

Cerevel Therapeutics (CERE) appointed Abraham N. Ceesay to the newly-created role of president, effective May 3, 2021.Serving most recently as CEO at Tiburio Therapeutics, a privately-held biotechnology company, he has almost 20 years experience leading operations at a number of biopharm...

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Abraham N. Ceesay to the newly-created role of president, effective ...

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission Data readouts from tavapadon Phase 3 TEMPO program expected beginning in the first half of 2023 ...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2020 Q4 - Results - Earnings Call Presentation

Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2020 Earnings Conference Call March 24, 2021 08:00 ET Company Participants Matt Calistri - Vice President, Investor Relations Tony Coles - Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Kathy Yi ...

Cerevel Therapeutics (CERE): Q4 GAAP EPS of -$0.27.Cash and cash equivalents of $383.6MPress Release For further details see: Cerevel Therapeutics reports Q4 results